Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

  • Sort by:
  • Browse by:
<< first | < prev next > | last >>
sessions: 1 to 25 of 48
page: of 2 records per page:
Opening Plenary: Planning for Success (and the Challenges Ahead)
Welcome to HIVR4P 2018
Jose Alcamí
Instituto de Salud Carlos III, Spain
Desmond Tutu Award for HIV Prevention and Human Rights
Georgia Tomaras
Duke University, United States
HIV Vaccines: Where Are We and What Next?
Linda-Gail Bekker
Desmond Tutu HIV Centre, University of Cape Town, South Africa
Novel Trial Designs for a Complex Environment
Sheena McCormack
MRC Clinical Trials Unit at UCL, United Kingdom
Ending the HIV/AIDS Pandemic: The Critical Role of HIV Prevention Science
Anthony Fauci
National Institute of Allergy and Infectious Diseases, NIH, United States
The Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy
Manju Chatani-Gada
AVAC, United States
HIVR4P 2018 Scholars
Mike Chirenje
University of Zimbabwe, Zimbabwe
from HIV Research for Prevention 2018 on 22 October 2018 16:00-18:00
Plenary 02: What Happens First: Understanding Susceptibility, Transmission and Early Infection
Visualizing HIV Transmission and Prevention
Thomas Hope
Northwestern University, United States
First Responders: What Early Infection Teaches About Prevention and Functional Cure Strategies
Thumbi Ndung’u
University of KwaZulu-Natal, South Africa
Untangling Hormonal Impacts on the Vaginal Microbiome and HIV Acquisition Risk
Sharon Achilles
University of Pittsburgh, United States
from HIV Research for Prevention 2018 on 23 October 2018 08:30-10:00
Oral Abstract Session 01: Location, Location, Location: Mucosal Mediators of Risk
Role of Epithelial Cells and Fibroblasts From the Female Reproductive Tract in TFV and TAF Protection of CD4+ T Cells from HIV Infection
Charles Wira
Geisel School of Medicine at Dartmouth, United States
Optical Tissue Imaging and Spectroscopic Measurement of Spatiotemporal Tenofovir Distribution, Partitioning and Diffusivity in Vaginal and Rectal Mucosa
Oranat Chuchuen
Khon Kaen University, Faculty of Engineering, Thailand
Transplanted Human Vaginal Microbiomes Alter HIV-1 Infection and Tenofovir Efficacy in Colonized Vaginal Epithelial Multilayer Cultures
Richard Pyles
University of Texas Medical Branch, United States
Impact of Vaginal Bacteria Communities on Antiretroviral-based PrEP Drug Metabolism
Ryan Cheu
University of Washington, United States
Hormonal Contraception Induced Changes to the Female Genital Microbiota in South African Adolescents: A Randomized, Crossover Trial
Christina Balle
University of Cape Town, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, South Africa
Reducing Inflammation as a Novel HIV Prevention Approach: Aspirin Reduces Inflammation and HIV Target Cells at the Female Genital Tract
Keith R Fowke
University of Manitoba, Canada
from HIV Research for Prevention 2018 on 23 October 2018 10:30-12:00
Oral Abstract Session 02: Immunity in Human Vaccine Trials
T-cell and Transcriptomic Responses to Prime-boost Strategies of 3 HIV Vaccines (MVA HIV-B; LIPO-5; GTU-MultiHIV B) - ANRS/INSERM VRI01 Trial
Jean-Daniel Lelièvre
Vaccine Research Institute/VRI, Hôpital Henri Mondor, France
Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial
Gregory Wilson
Vanderbilt University Medical Center, United States
V1V2 IgG and Antibody Fc Effector Functions in a Subtype C ALVAC-HIV and Bivalent Subtype C gp120/MF59 HIV-1 Vaccine Trial in South Africa
Xiaoying Shen
Duke Human Vaccine Institute, United States
DNA-prime Induces Higher Magnitude Humoral Responses Than ALVAC-prime in HIV Vaccine Regimens With the Same Protein Boost
Zoe Moodie
Fred Hutchinson Cancer Research Center, United States
Vaccine-induced Gene Signature Correlates With Protection Against Acquisition in Three Independent Vaccine Efficacy Trials Including RV144
Rasmi Thomas
US Military HIV Research Program (MHRP), Walter Reed Army Institute of Research, United States
Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens
Daniel J. Stieh
Janssen Vaccines & Prevention B.V., Netherlands
from HIV Research for Prevention 2018 on 23 October 2018 10:30-12:00
Oral Abstract Session 03: Structure and Maturation of bNAbs
Induction and Maturation of HIV-1 Fusion Peptide-directed Broadly Neutralizing Antibodies in Rhesus Macaques by Vaccination
Peter D. Kwong
Vaccine Research Center, United States
Identification of Near Pan-neutralizing Antibodies Against HIV-1 by Deconvolution of Plasma Humoral Responses
Mohammad Sajadi
Institute of Human Virology, School of Medicine, University of Maryland, United States
Structural Basis for Germline VRC01 Antibody Recognition of a Glycosylated HIV-1 Envelope CD4-binding Site
Marie Pancera
Fred Hutchinson Cancer Research Center, United States
Fast and Focused Maturation of VH1-2-restricted HIV-env CD4-binding Site Targeting bNAbs
Elise Landais
International AIDS Vaccine Initiative (IAVI), United States
Somatic hypermutation to counter a rare viral immunotype drove off-track antibodies in the CAP256-VRC26 V2-directed bNAb lineage
David Sacks
National Institute for Communicable Diseases, National Health Laboratory Service, South Africa
New SHIV Models of bNAb Elicitation and Env-Ab Coevolution
Hui Li
University of Pennsylvania, United States
from HIV Research for Prevention 2018 on 23 October 2018 10:30-12:00
Oral Abstract Session 04: Entry Into the PrEP Continuum
Tracking Global Oral PrEP Provision: The Who, What, Where of Oral PrEP
Laura Fitch
AVAC, United States
Sexual Health Goal Congruence and PrEP Adoption Among Gay and Bisexual Men in Primary Partnerships
Kristi Gamarel
University of Michigan School of Public Health, United States
Characterization of Early Adopters in a National Oral Pre-exposure Prophylaxis (PrEP) Scale-up Program in Kenya
Daniel Were
Jhpiego, Kenya
“So That I Don't Get Infected Even If I Have Sex With Someone Who Is Positive:” Factors Influencing PrEP Uptake Among Young Women in Kenya
Nicholas Thuo
Partners in Health Research and Development, Kenya
HIV-related Risks and Interest in Pre-exposure Prophylaxis (PrEP) Among Transgender Respondents of the Community-based Survey Flash! PrEP in Europe
Rosemary M. Delabre
Coalition PLUS, Community-based Research Laboratory, France
Substantial Gaps in the PrEP Continuum Among Transwomen Compared With MSM in San Francisco
Albert Liu
San Francisco Department of Public Health, United States
from HIV Research for Prevention 2018 on 23 October 2018 10:30-12:00
Oral Abstract Session 05: If I Choose, Will I Use? Products, People and Preferences
Acceptability of Long-acting Injectable Cabotegravir (CAB LA) in HIV-uninfected Individuals: HPTN 077
Elizabeth (Betsy) Tolley
FHI 360, United States
Partners, Peers and Rumours as Influencers of Use and Attitudes Towards the Dapivirine Vaginal Ring: Qualitative Data From The Ring Study (IPM 027)
Cecilia Milford
MatCH Research Unit (MRU), University of the Witwatersrand, South Africa
Testing Objective Markers of Placebo Vaginal Product Adherence in the Field
Andrea Ries Thurman
CONRAD Eastern Virginia Medical School, United States
Preference and Choice of Four Vaginal HIV Prevention Placebo Dosage Forms Among Young African Women: Results of the Quatro Randomized Crossover Trial
Elizabeth Montgomery
RTI International, United States
Attribute Preferences for Long-acting Pre-exposure Prophylaxis (PrEP): Results of a Discrete Choice Experiment With South African Youth
Alexandra Minnis
RTI International, United States
UChoose: An Adolescent Study of HIV Prevention Choice in Cape Town, South Africa
Katherine Gill
Desmond Tutu HIV Foundation, South Africa
from HIV Research for Prevention 2018 on 23 October 2018 13:00-14:30
Oral Abstract Session 06: Mucosal Models of Prevention
Combination of MUC5AC and MUC2 Enhances Antibody Neutralization Potency Against HIV-1 Infection
Arangassery Rosemary Bastian
Northwestern University, United States
Neutrophil Extracellular Traps Represent a Novel Mechanism for HIV Prevention in the Female Genital Tract
Marta Rodriguez-Garcia
Geisel School of Medicine at Dartmouth, United States
Select V2 Loop Antibodies Inhibit gp120 Binding to Integrin a4ß7
Sakaorat Lertjuthaporn
Faculty of Medicine Siriraj Hospital, Thailand
Investigating the Interactions Between HIV and a New Epithelial Target Cell in Human Genital Tissue
Jake Rhodes
Westmead Institute for Medical Research, Australia
Live Imaging of HIV-1 Transfer Across T-cell Virological Synapse to Epithelial Cells That Promotes Stromal Macrophage Infection
Morgane Bomsel
Institut Cochin CNRS UMR8104, France
Fca-receptor I Expression by Stratified Squamous Epithelia: Implications for IgA-associated Immune Function in the Human Lower Genital Tract
Kadryn Kadasia
Boston University School of Medicine, United States
from HIV Research for Prevention 2018 on 23 October 2018 13:00-14:30
Oral Abstract Session 07: Understanding Protection Against HIV From the T Cell Perspective
Increased Breadth of T-cell Responses After Mosaic HIV Vaccination in Humans (HVTN 106)
Nicole Frahm
Fred Hutchinson Cancer Research Center, United States
Gag and Env Conserved Element DNA Vaccines Elicit Cytotoxic Responses Targeting Subdominant Epitopes Able to Recognize Infected Cells in Macaques
Barbara K. Felber
National Cancer Institute at Frederick, United States
Utilizing Computational Machine Learning Tools to Understand Immunogenic Breadth of HIV in the Context of a CD8 T-cell Mediated HIV Response
Jonathan Hare
International AIDS Vaccine Initiative (IAVI), United Kingdom
Structure-based Network Analysis of HIV-1 Defines Protective CD8+ T Cell Epitopes Across Diverse HLA: Implications for Global Immunogen Design
Gaurav Gaiha
Ragon Institute of MGH, MIT & Harvard, United States
CD8+ T Cells Do Not Control SIV Replication During ART or Viral Relapse After ART Withdrawal
Afam Okoye
Oregon Health & Science University, United States
CD8 T Cells Responding to Adapted Epitopes Are Enriched in Chronic HIV Infection and Induce Dendritic Cell Maturation with Enhanced CD4 Infection
Kai Qin
University of Alabama at Birmingham, United States
from HIV Research for Prevention 2018 on 23 October 2018 13:00-14:30
Oral Abstract Session 08: bNAbs for Prevention
Combination of HIV-1 Antibodies 3BNC117 and 10-1074 Delays Viral Rebound During Treatment Interruption
Pilar Mendoza
Rockefeller University, United States
SHIV162P3 Transmission by Semen Leukocytes Is Efficiently Inhibited by a Combination of Broad Neutralizing Antibodies
Karunasinee Suphaphiphat
CEA, France
Broadly Neutralizing Antibodies Provide Potent Dose-dependent Protection to Rhesus Macaques Against Mucosal SHIV Challenge
Amarendra Pegu
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States
VRC01 Pharmacokinetics at Mucosal Sites in HIV-infected and Healthy Adults
Madhu SP Prabhakaran
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States
Safety and Pharmacokinetics of Multiple Doses of a Potent Anti-HIV Monoclonal Antibody, VRC01, in HIV-exposed Newborns
Coleen Cunningham
Duke, United States
Imaging the Distribution of I.V.-injected VRC01 and VRC01-LS in the In Vivo Rhesus Macaque Model
Ann M. Carias
Northwestern University, United States
from HIV Research for Prevention 2018 on 23 October 2018 13:00-14:30
Symposium 01: We Want bNAbs: Passively Infused and Induced by Vaccines
Engineered Tandem Bispecific Neutralising Antibody for HIV-1 Prevention and Immunotherapy
Zhiwei Chen
The University of Hong Kong AIDS Institute, China
Antibody Mediated Protection (AMP): Where Are We? Which Antibodies to Use and How Will We Know If It´s Working?
Lynn Morris
National Institute for Communicable Diseases of the NHLS, South Africa
Generation of Immunogens Based on HIV-1 Envelopes From Patients With Broadly Neutralizing Responses Within the First 6 Months of Infection
Eloisa Yuste
Instituto de Salud Carlos III, Spain
HIV-1 Vaccine Design for the Elicitation of V3-glycan Broadly Neutralizing Antibodies
Kevin Saunders
Duke Human Vaccine Institute, United States
Progress in Germline-targeting Vaccine Design for HIV
William Schief
The Scripps Research Institute and IAVI, United States
from HIV Research for Prevention 2018 on 23 October 2018 15:00-16:30
Symposium 02: Early Invaders: Establishment of HIV Infection
Selection of Transmitted Founder Viruses During Sexual HIV-1 Acquisition
Manish Sagar
Boston University, United States
Identification of a New HIV Transmitting Target Cell in Human Genital Tissue
Andrew Harman
The Westmead Institute, University of Sydney, Australia
Characteristics Leading to HIV Trapping in the Female Genital Tract and Systemic Primary Infection During Transmission
Eric Arts
University of Western Ontario, Canada
Mucosal Immunology in the Context of Acute HIV Infection and HIV Remission Studies
Alexandra Schuetz
MHRP Thailand, Thailand
from HIV Research for Prevention 2018 on 23 October 2018 15:00-16:30
Symposium 03: Beyond Placebo: Designing and Implementing Next Generation HIV Prevention Trials
Regulatory Perspectives for Streamlining HIV Prevention Trials
Jeffrey Murray
FDA, United States
Novel Trial Design in the Era of Successful HIV Prevention Interventions
Deborah Donnell
Fred Hutchinson Cancer Research Center, United States
The Landscape is Changing… [It's] Quite a Complicated Issue" : Perspectives on the Standard of Prevention in South African HIV Vaccine Trials
Zaynab Essack
Human Sciences Research Council, South Africa
Strengthen Community Expertise on the Important Aspects of Clinical Trial Design
Luciana Kamel
Fiocruz, Brazil
Community Engagement in the Design and Implementation of HIV Prevention Trials: Uganda Virus Research Institute-International AIDS Vaccine Initiative
Gertrude Nanyonjo
UVRI-IAVI HIV Vaccine Program, Uganda
Questions
Jeffrey Murray
FDA, United States
Deborah Donnell
Fred Hutchinson Cancer Research Center, United States
Zaynab Essack
Human Sciences Research Council, South Africa
Luciana Kamel
Fiocruz, Brazil
Gertrude Nanyonjo
UVRI-IAVI HIV Vaccine Program, Uganda
from HIV Research for Prevention 2018 on 23 October 2018 15:00-16:30
Symposium 04: ARVs for Prevention: Extrapolating from Data to Clinical Practice
Pharmacokinetics of PrEP Agents: Where Do Drugs Go? How Long Do They Last?
Marta Boffito
Chelsea and Westminster NHS Trust, United Kingdom
Lessons Learned from Pre-clinical Animal Models on Pharmacokinetics and Pharmacodynamics of ARVs for PrEP
Charles Dobard
Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Laboratory Branch, United States
Understanding PrEP Effectiveness in Different Populations in the Context of Public Health Programs
Irene Mukui
National AIDS & STI Control Program, Kenya
The PrEP Paradigm for Prevention, Advocacy and Implementation in sub-Saharan Africa: Strong Starts, Short Cuts, and the Use (and Abuse?) of Data
Emily Bass
AVAC, United States
from HIV Research for Prevention 2018 on 23 October 2018 15:00-16:30
Plenary 03: The Future is Now: Next Steps in Developing New Prevention Options
Beyond TDF/FTC: The Future of Systemic Pre-exposure Prophylaxis
Raphael Landovitz
UCLA Center for Clinical AIDS Research & Education, United States
On-demand Topical Agents for HIV Pre-exposure Prophylaxis
Craig Hendrix
Johns Hopkins University, United States
Vaccine Design 2.0: The Pipeline Novel HIV-1 Envelope Proteins to Induce Neutralizing Antibodies
Rogier Sanders
Amsterdam University Medical Centers (Amsterdam UMC), University of Amsterdam, Netherlands
from HIV Research for Prevention 2018 on 24 October 2018 08:30-10:00
Oral Abstract Session 09: Translating Immunity From Pre-clinical Animal Models to Humans
Co-crystal Structure of SIVmac239 gp120 with rhCD4 and Neutralizing Antibody ITS90.03 Reveals Similar Sites of Vulnerability Between HIV-1 and SIV Env
Jason Gorman
NIH/NIAID/VRC, United States
Native HIV-1 Env Circulating During the Development of Breadth in Human Subjects Elicits Tier 2 Heterologous Neutralizing Monoclonal Antibodies in NHP
Ann Hessell
Oregon Health and Science University, United States
Macaque SHIV Induction of 2G12-like Broadly Neutralizing Antibodies
Wilton Bryan Williams
Duke University, United States
Tight Control of SHIV BaL.P4 Challenge in Rhesus Macaques Co-immunized With DNA and Protein HIV Vaccine Regimen
Miroslaw K. Gorny
New York University School of Medicine, Department of Pathology, United States
Tracking Cy5-conjugated VRC01 Following IV Injection in the Rhesus Macaque Reveals That Tissue Distribution Can Take 1 Week to Achieve Steady State
Jeffrey Schneider
Northwestern University, United States
A Meta-analysis to Evaluate the Relationship Between Serum Antibody Neutralizing Titer and Protection Against SHIV Challenge in Nonhuman Primates
Ying Huang
Fred Hutchinson Cancer Research Center, United States
from HIV Research for Prevention 2018 on 24 October 2018 10:30-12:00
Oral Abstract Session 10: Key to the Response: Populations, Partners and Prevention
Male Partners of Adolescent Girls and Young Women (AGYW) in Durban, South Africa: How High Is Their HIV Risk and What Groups Are Most at Risk?
Ann Gottert
Population Council, United States
Help-seeking Behavior of Women Reporting Intimate Partner Violence in Mwanza, Tanzania, and Its Implications for HIV: Findings From the MAISHA Study
Sheila Harvey
London School of Hygiene & Tropical Medicine, United Kingdom
Undercurrents of Sex Work: Characteristics and Experiences of Female Sex Workers in Kisumu, Kenya
Kawango Agot
Impact Research & Development Organization, Kenya
HIV Incidence Among Men Who Have Sex With Men and Transgender Women in Sub-Saharan Africa: Findings From the Multi-country HPTN 075 Cohort Study
Theo G.M. Sandfort
New York State Psychiatric Institute, United States
Young Transwomen in Brazil Have High HIV Risk and Low Prevention Use
Erin C Wilson
San Francisco Department of Public Health, United States
An Integrated Intervention to Increase ART and MAT Reduces Mortality Among PWID: Results From the HPTN 074 Randomized Trial
Kostyantyn Dumchev
Ukrainian Institute on Public Health Policy, Ukraine
from HIV Research for Prevention 2018 on 24 October 2018 10:30-12:00
Oral Abstract Session 11: Novel Vaccine Strategies
Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to an HIV-1 Clade C Envelope Vaccine
Robin Shattock
Imperial College, United Kingdom
Fusion Peptide-directed Antibodies Elicited in Immunized Rhesus Macaques Neutralized 59% of 208 Wildtype HIV-1 Strains
Rui Kong
Vaccine Research Center, NIAID, NIH, United States
Vaccination of Rabbits and Macaques With V1V2-scaffold Immunogens Induces V1V2-specific Antibody Responses With Antiviral Functions
Svenja Weiss
Icahn School of Medicine at Mount Sinai, United States
Immune Control of SHIV Infection in Rhesus Macaques by PD-1-based Vaccine
Yik Chun Wong
AIDS Institute, The University of Hong Kong, Hong Kong
Vaccine-elicited Cross-neutralizing HIV Antibodies (bNAbs) to Two Env Sites of Vulnerability Following Heterologous NFL Trimer Liposome Prime: Boosting
Richard Wyatt
IAVI Neutralizing Antibody Center at Scripps, United States
Immune Responses to PENNVAX-GP (R) HIV DNA Vaccine Plus IL-12 Are Equivalent or Superior When Delivered by Intradermal vs. Intramuscular Electroporation
Srilatha Edupuganti
Emory University, United States
from HIV Research for Prevention 2018 on 24 October 2018 10:30-12:00
Symposium 11: ARVs for Prevention in Women of Childbearing Age
No Woman Left Behind: An Ethical Framework for Prevention Studies in Reproductive Age Women
Annie Lyerly
University of North Carolina, United States
Efavirenz and Dolutegravir: A Tale of Two ARVs
Elaine Abrams
Columbia University, United States
Studying Periconception Outcomes in Women on ARVs in Brazil
Adele Benzaken
Ministry of Health, Brazil, Brazil
Striking a Balance
Sharon Hillier
University of Pittsburgh, United States
from HIV Research for Prevention 2018 on 24 October 2018 10:30-12:00
Oral Abstract Session 12: Contraception and HIV Risk: Still Between a Rock and a Hard Place
MPA, Used in Injectable Contraception, Increases HIV-1 Replication ex vivo by a Different Mechanism Compared to Luteal Phase Progesterone Levels
Chanel Avenant
University of Cape Town, South Africa
Safety and Pharmacokinetics of Dapivirine and Levonorgestrel Vaginal Rings for Multipurpose Prevention of HIV and Pregnancy
Sharon Achilles
University of Pittsburgh, United States
Increased CCR5 Levels Result in Increased R5-HIV Replication by Medroxyprogesterone Acetate, Unlike Norethisterone, via the Glucocorticoid Receptor
Janet Hapgood
University of Cape Town, South Africa
Effect of Depot-medroxyprogesterone Acetate on T Cell Expression of Immunosuppressive Markers, PD-1 and CTLA-4 in HIV-negative Women
Taguma A Matubu
University of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Zimbabwe
Successful Use of Safer Conception Strategies Resulting in High Pregnancy Rates and no HIV Transmissions Among Kenyan HIV-discordant Couples
Renee Heffron
University of Washington, United States
Risk of HIV-1 Acquisition Among South African Women Using a Variety of Contraceptive Methods in a Prospective Study
Thesla Palanee-Phillips
Wits Reproductive Health and HIV Institute, South Africa
from HIV Research for Prevention 2018 on 24 October 2018 13:00-14:30
Oral Abstract Session 13: Virus Control: Therapeutic Interventions
Setting the Stage for Meaningful Community Engagement and Participation in HIV Cure-related Research: Lessons Learned From the HIV Prevention Field
Melissa Hermerding
Forum for Collaborative Research, University of California, Berkeley, School of Public Health, United States
A Novel Approach to Inhibit CD4 Exhaustion: Results of a Placebo-controlled Phase II Study of a gp41 Peptide Vaccine in HIV-1 Patients Under ART
Behazine Combabière
CIMI-Paris, France
DNA-GTU/LIPO-5 Vaccine Followed by Supervised Treatment Interruption (STI) in a Therapeutic HIV Phase II Randomized Trial: VRI02 ANRS 149 LIGHT
Christine Lacabaratz
Vaccine Research Institute/VRI, France
Therapeutic Vaccination With a Combination of IDLV-SIV-Gag and IDLV-PGT121 Results in Prolonged Virus Control in Chronically SHIV-infected Macaques
Maria Blasi
Duke University Medical Center, United States
Long-term Delivery of Anti-HIV Monoclonal Antibodies
Jose M. Martinez-Navio
University of Miami - Miller School of Medicine, United States
Tissue Viral Seeding Drives SHIV Pathogenesis in Infant Macaques and Is Reduced by Early bNAb Therapy
Ann Hessell
Oregon Health and Science University, United States
from HIV Research for Prevention 2018 on 24 October 2018 13:00-14:30
Oral Abstract Session 14: Antibody Functions Beyond Neutralization
HIV gp120 V2 Mimics IgSF Domain 1 of MAdCAM, the Natural Ligand of Integrin a4ß7
James Arthos
NIAID, NIH, United States
IgG3 Hinge Length Enhances Neutralization Potency and Fc Effector Function of an HIV V2-specific Broadly Neutralizing Antibody
Simone Irene Richardson
Centre for HIV & STIs, National Institute for Communicable Diseases, South Africa
Neutralizing and ADCC Activity of Anti-HIV-1 Antibodies Against Acute Subtype C Envs: Implications for Prevention and Treatment of HIV-1 Infection
Dieter Mielke
Duke University, United States
Structural Characterization of Rhesus Macaque Fc Domains of IgG1-4 and the FcγRIIIa1-IgG1Fc Complex
William Tolbert
Institute of Human Virology, University of Maryland, School of Medicine, United States
IgA Inhibits HIV-specific Antibody-dependent Neutrophil Phagocytosis
Matthew Worley
The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Australia
Tight Control of SHIVBaL in Rhesus Macaques Immunized With gp160 DNA + gp120 Proteins (Clades E and B) Correlates With V2p Antibodies
Svenja Weiss
Icahn School of Medicine at Mount Sinai, United States
from HIV Research for Prevention 2018 on 24 October 2018 13:00-14:30
Oral Abstract Session 15: New ARVs for Prevention
Pharmacokinetic and Pharmacodynamic Evaluation of the Antiretroviral Compound MK-2048 Released From an Intravaginal Ring in Rhesus Macaques
James Cummins
Division of AIDS, NIAID, NIH, United States
Efficacy of UAMC01398 Gel Formulation in NHP Model of HIV Vaginal Transmission
Delphine Desjardins
CEA Université Paris Sud, Inserm u1184, IDMIT Department, France
Dose-ranging Pharmacokinetic Assessment of Vaginally Administered EVG/TAF Inserts in Macaques for PrEP
Charles Dobard
Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Laboratory Branch, United States
HIV Prevention in Healthy Women: Safety and Pharmacokinetics of a Potential New Tenofovir Alafenamide Fumarate (TAF)-based Oral PrEP Regimen
Jill Schwartz
CONRAD Eastern Virginia Medical School, United States
Cabotegravir (CAB) Long-acting (LA) Phase 3 (Ph3) PrEP Dose Selection Based on Population Pharmacokinetics (PPK) in Healthy and HIV-infected Adults
Susan Ford
PAREXEL International, United States
Tail-phase Safety, Tolerability and Pharmacokinetics of Long-acting Injectable Cabotegravir in HIV-uninfected Individuals: HPTN 077 Final Results
Raphael Landovitz
UCLA Center for Clinical AIDS Research & Education, United States
from HIV Research for Prevention 2018 on 24 October 2018 13:00-14:30
Round Table 01: Accelerating Product Introduction for Impact
Preparing for Successful Implementation of Prevention Strategies
Hasina Subedar
Department of Health, South Africa
Learning From the Past: Planning for Future Success in Implementing Biomedical HIV Prevention Products
Alex Coutinho
Partners in Health, Rwanda
Successes and Shortcomings in Introducing Sexual and Reproductive Health Technologies: Insights From End-users, Providers and Policy Makers
Martha Brady
PATH, United States
Learning from History: Roll-out of Non-HIV Vaccines
Swati Gupta
International AIDS Vaccine Initiative, United States
Introduction of New Health Technologies in HIV Prevention and Treatment Trials: Best Practices of Community Engagements and Communication in Peru
Maria del Rosario Leon
Impacta Salud y Educacion, Peru
Questions
Hasina Subedar
Department of Health, South Africa
Alex Coutinho
Partners in Health, Rwanda
Martha Brady
PATH, United States
Swati Gupta
International AIDS Vaccine Initiative, United States
Maria del Rosario Leon
Impacta Salud y Educacion, Peru
from HIV Research for Prevention 2018 on 24 October 2018 15:00-16:30
Symposium 05: Close Encounters of the Third Kind: Innate and Adaptive Immune Responses in HIV Dissemination
Interfering with Interferons: How HIV Subverts the Interferon System to Facilitate Sexual HIV Transmission
Anthony Cunningham
The Westmead Institute, The University of Sydney, Australia
Fixed Characteristics of HLA Class I Alleles That Impact HIV Disease
Mary Carrington
Frederick National Laboratory for Cancer Research, United States
HIV Persistence and the Immune Microenvironment in Lymph Nodes Following Initiation of cART During Hyperacute HIV-1 Infection
Zaza Ndhlovu
University of KwaZulu Natal, South Africa
The First Line Against HIV/SIV: Innate Immune Effectors at the Virus-Mucosae Interface
R. Keith Reeves
Beth Israel Harvard, United States
from HIV Research for Prevention 2018 on 24 October 2018 15:00-16:30
<< first | < prev next > | last >>
sessions: 1 to 25 of 48
page: of 2 records per page: